Foundayo vs Ozempic: New Pill vs Proven Injection
Ozempic has been the dominant GLP-1 for years. Now Foundayo enters as a cheaper, oral alternative. Ozempic is FDA-approved for diabetes (widely used off-label for weight loss), while Foundayo is approved specifically for weight management. Here's the full comparison.
The Key Differences
These are fundamentally different drugs despite both being GLP-1 medications:
- Different molecules: Ozempic is semaglutide (a peptide); Foundayo is orforglipron (a small molecule, non-peptide)
- Different mechanism intensity: Ozempic is a full GLP-1 agonist; Foundayo is a partial agonist
- Different delivery: Weekly injection vs daily pill
- Different FDA indications: Ozempic is for diabetes; Foundayo is for weight management
Why this matters: If you're using Ozempic off-label for weight loss and it's working, there may not be a strong reason to switch — unless cost, convenience, or injection fatigue is an issue.
Cost: Foundayo Is Dramatically Cheaper
This is where the comparison gets stark:
- Ozempic: ~$936/month list price. One price for all doses.
- Foundayo: $149/month (starting) to $349/month (max). Lilly specifically priced it to undercut injectables.
At the starting dose, Foundayo is 84% cheaper than Ozempic. Even at the highest dose, it's still 63% cheaper. For uninsured or underinsured patients, this price difference is life-changing.
With savings cards, both drop to $25/month — but savings cards have eligibility requirements and don't work with Medicare or Medicaid.
Weight Loss Results
Ozempic at 2.0mg: In STEP-equivalent analyses, semaglutide 2.0mg shows approximately 15% weight loss. Note: Ozempic's max approved dose is 2.0mg (vs Wegovy's 2.4mg).
Foundayo at highest dose: 12.4% weight loss in ATTAIN-1 (completers at 36mg trial dose).
Ozempic has a modest efficacy advantage (~3 percentage points), but Foundayo's results are clinically meaningful — 27 lbs average weight loss at the highest dose.
A head-to-head comparison was published in The Lancet (the ATTAIN-3 trial, Lilly-funded): In type 2 diabetes patients, orforglipron outperformed oral semaglutide (Rybelsus 7-14mg) on weight loss and A1C reduction. However, Novo Nordisk pointed out this used their lower diabetes dose, not the higher weight management dose.
Compare Your Personalized Switch Plan
Frequently Asked Questions
Sources
- ATTAIN-1 Phase 3 Trial — orforglipron weight loss data
- SUSTAIN / STEP Trial Programs — semaglutide data
- ATTAIN-3 (Lancet, 2026) — orforglipron vs oral semaglutide head-to-head
- Foundayo FDA Prescribing Information
- Ozempic FDA Prescribing Information
Stay Updated
Get notified when Foundayo pricing changes, new GLP-1 options become available, or new switching data is published.
No spam. Unsubscribe anytime. We never share your email.
Ready to Make the Switch?
Talk to a doctor about switching to your new medication. These telehealth providers offer online consultations and GLP-1 prescriptions.
MedSwitcher may earn a commission from some providers. This does not affect our recommendations. Our switch plans are based on clinical data, not partnerships.